NO20070580L - Behandling av cancer. - Google Patents

Behandling av cancer.

Info

Publication number
NO20070580L
NO20070580L NO20070580A NO20070580A NO20070580L NO 20070580 L NO20070580 L NO 20070580L NO 20070580 A NO20070580 A NO 20070580A NO 20070580 A NO20070580 A NO 20070580A NO 20070580 L NO20070580 L NO 20070580L
Authority
NO
Norway
Prior art keywords
cancer
treatment
leukemia
compositions
relates
Prior art date
Application number
NO20070580A
Other languages
English (en)
Inventor
James Peter Burnie
Ruth Christine Matthews
Tracey Carter
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0414885A external-priority patent/GB0414885D0/en
Priority claimed from GB0420845A external-priority patent/GB0420845D0/en
Priority claimed from GB0503566A external-priority patent/GB0503566D0/en
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Publication of NO20070580L publication Critical patent/NO20070580L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Sammendrag 0. nr. P60603668NO00 Den foreliggende oppfinnelsen er relatert til nye medikamenter og preparater som omfatter effektive anti-kreftmidler sammen med et anti-Hsp90 antistoff som sammen tilveiebringer en forsterket virkeevne i behandlingen av kreft og leukemi.
NO20070580A 2004-07-02 2007-01-31 Behandling av cancer. NO20070580L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0414885A GB0414885D0 (en) 2004-07-02 2004-07-02 Cancer therapy
GB0420845A GB0420845D0 (en) 2004-09-20 2004-09-20 Treatment of cancer
US61442304P 2004-09-30 2004-09-30
GB0503566A GB0503566D0 (en) 2005-02-21 2005-02-21 Treatment for cancer
US65445805P 2005-02-22 2005-02-22
PCT/GB2005/002545 WO2006003384A1 (en) 2004-07-02 2005-06-30 Treatment of cancer

Publications (1)

Publication Number Publication Date
NO20070580L true NO20070580L (no) 2007-03-19

Family

ID=39092324

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070580A NO20070580L (no) 2004-07-02 2007-01-31 Behandling av cancer.

Country Status (9)

Country Link
US (1) US20080038267A1 (no)
EP (1) EP1763366A1 (no)
KR (1) KR20070050918A (no)
CN (1) CN101010100A (no)
AU (1) AU2005259002B2 (no)
CA (1) CA2572318A1 (no)
NO (1) NO20070580L (no)
RU (1) RU2389507C2 (no)
WO (1) WO2006003384A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
BRPI0710496A2 (pt) * 2006-04-07 2011-08-16 Novartis Ag combinação que compreende a) composto de pirimidilaminobenzamida e b) inibidor de thr315iie cinase
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
CN104678106B (zh) * 2008-08-18 2016-12-07 中胚有限公司 单克隆抗体stro-4
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
WO2015183978A1 (en) * 2014-05-28 2015-12-03 Agensys, Inc. Derivatives of dolaproine-dolaisoleuine peptides
US20150342961A1 (en) * 2014-06-03 2015-12-03 Hai-Hui Xue Use of prostaglandin e1 (pge1) and misoprostol for treating chronic myelogenous/myeloid leukemia (cml)
EP3267975A4 (en) 2015-03-09 2018-08-08 The Regents of the University of California Polymer-drug conjugates for combination anticancer therapy
US10457726B2 (en) * 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
KR102184377B1 (ko) 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
WO2019160383A1 (ko) * 2018-02-19 2019-08-22 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
CN111116743B (zh) * 2018-10-30 2022-01-28 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
WO2021183318A2 (en) * 2020-03-09 2021-09-16 President And Fellows Of Harvard College Methods and compositions relating to improved combination therapies
CN115957328A (zh) * 2022-07-13 2023-04-14 杭州百可生物科技有限公司 一种用于治疗白血病的药物组合物以及白血病的治疗方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
AU769235B2 (en) * 1999-04-09 2004-01-22 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
GB0008305D0 (en) 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections

Also Published As

Publication number Publication date
EP1763366A1 (en) 2007-03-21
KR20070050918A (ko) 2007-05-16
CA2572318A1 (en) 2006-01-12
RU2389507C2 (ru) 2010-05-20
AU2005259002A1 (en) 2006-01-12
AU2005259002B2 (en) 2011-01-27
CN101010100A (zh) 2007-08-01
US20080038267A1 (en) 2008-02-14
RU2007104053A (ru) 2008-08-10
WO2006003384A1 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
ATE531263T1 (de) Hemmer der bruton-tyrosinkinase
DE602004013563D1 (de) Rantagonisten
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
CY1105349T1 (el) Θειαζολυλ-αναστολεις τυροκινασεων της οικογενειας tec
SE0301700D0 (sv) Novel compounds
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
DE602004012083D1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
EA201100032A1 (ru) Соединения пиридина
EA200900044A1 (ru) Замещенные производные 1,3-дифенилпропана, получение и их применение
DE60220771D1 (de) Hemmer von cyclinabhängigen kinasen als mittel gegen krebs
SG161318A1 (en) Heterocyclic inhibitors of mek and methods of use thereof
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
SE0300457D0 (sv) Novel compounds
ATE507218T1 (de) Benzodiazepin-derivate als rock-kinasen hemmer
ATE426409T1 (de) Antitumor-kombinationen mit vegf-trap und 5fu oder einem seiner derivate
MX2007000263A (es) Tratamiento de cancer.
TNSN06454A1 (en) Treatment of cancer
ECSP003318A (es) UREAS DIFENIL -w -CARBOXIARIL SUBSTITUIDAS COMO INHIBIDORES DE RAF QUINASA
CR6940A (es) Inhibidores de espiropirimidin-2,4,6-triona metaloproteinasa

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application